Ryan Specialty CRO Sells at $40: Analysts Targeting $50
Ryan Specialty's co-president and CRO Brendan Mulshine sold $1.62 million in stock at $40.51 in early September, weeks after the company posted a 23.3% earnings beat. Wall Street's consensus price tar
Ryan Specialty CRO Sells at $40: Analysts Targeting $50
NEW YORK, September 19, Ryan Specialty Holdings, Inc. (RYAN) finds itself at an unusual impasse: the executive closest to its revenue pipeline sold $1.62 million of stock at $40.51 in early September, weeks after the company posted a 23.3% earnings beat, while Wall Street's consensus price target of $50.53 sits nearly $10 above where he sold. Either the Street is chasing a number that insiders quietly reject, or the company's own revenue chief is leaving material upside unrealized.
The Numbers
Co-president and CRO Brendan Mulshine sold 40,000 shares at $40.51 on September 8, per SEC filings. Q2 2026 EPS of $0.74 beat consensus of $0.60 by 23.3%, per the July 30 8-K. Trailing-twelve-month revenues of $3.16 billion, up 7.4% year-over-year; $3.81 billion in total debt against $140 million in cash.
Insider Tape Contradicts the Earnings Trend
Ryan Specialty is a specialty insurance intermediary, a wholesale broker and program administrator connecting retail agents with carriers for complex, non-standard risks, earning fees and commissions without taking underwriting risk onto its own balance sheet. The Chicago-based firm, founded in 2010, has delivered back-to-back earnings beats: a 9.2% upside in Q1 2026, and a 23.3% beat in Q2.
The trailing 90-day insider record, however, shows $1.71 million in open-market sales against zero in open-market purchases. The reversal is stark: the company's Executive Chairman purchased 120,000 shares around mid-June 2026, per published reports, before Q2 results landed. The buying stopped when the beat was confirmed.
The RSU Sequence Matters, But Doesn't Explain Away the Exit Price
Four days before his open-market sale, Mulshine completed two share-conversion transactions of 40,000 shares each on September 4, the standard RSU-vesting-and-conversion sequence that typically precedes a sale. Routine mechanics. But the price at which he chose to sell is harder to dismiss: that level sits nearly 20% below the analyst consensus target and within cents of where the CFO's tax-withholding disposition settled in mid-July. Multiple insiders, across different transaction types, have clustered near the $40 level, which either reflects disciplined tax planning or a shared view on where the stock belongs.
HOW RYAN STACKS UP, data at publish
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| RYAN | $10.3B | 16.7x | -25.3% |
| CNM | $7.9B | 12.2x | -16.0% |
| HAYW | $2.8B | 13.4x | -12.5% |
| EQH | $14.7B | 6.0x | -0.2% |
| STEP | $6.0B | 13.6x | -30.8% |
| GSHD | $1.9B | 20.2x | -31.3% |
What Changes the Calculus
The forward checkpoint is the next earnings report. RYAN has now beaten estimates in three of the last four quarters, but the prior miss, $0.45 actual against a $0.49 estimate, shows the trajectory is uneven. If Q3 2026 delivers another double-digit beat, the gap between the insider sale price and the $50.53 consensus target starts to look like a timing error rather than a valuation signal. If it doesn't, Mulshine's exit near $40 will look prescient.
Run the free Ryan Specialty Holdings, Inc. deep-dive → to track the numbers as they develop. Current fundamentals, valuation and filing history for Ryan Specialty Holdings, Inc. (RYAN) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Ryan Specialty's Co-president and Chief Revenue Officer sold $1.62 million of stock at $40.51 in early September — weeks after the company posted a 23.3% earnings beat — while the Wall Street consensus price target sits at $50.53, nearly $10 above where the insider sold.